BIO Investor Forum 2007 Draws Record Crowd of Investment, Biotechnology and Pharmaceutical Leaders
WASHINGTON, D.C. (October 15, 2007) -- The BIO Investor Forum drew 1,237 registered professionals from the investment community, industry executives and the media. The conference was hosted by BIO and supported by Pacific Growth Equities; Acumen BioFin, a Division of Rodman & Renshaw; Jefferies & Company; RBC Capital and Bank of America. The conference was held October 9-11 at the Palace Hotel in San Francisco, Calif.
“Investors are looking for good science and a compelling story with an understanding of where a company is in the development process and the annual Investor Forum offers them a unique opportunity to learn about and explore opportunities with emerging companies that have promising science to share,” said Alan Eisenberg, BIO’s executive vice president of emerging companies and business development.
The fourth annual BIO Investor Forum occured against the backdrop of a fairly positive financing environment with most analysts anticipating positive growth in investment activity for the fourth quarter of 2007. Roundtables on financial issues such as biotech turnaround investments, cross-over investors and IPOs and exit strategies provided attendees with advice from industry experts on how to navigate the current environment. There were also 204 public and venture-stage company presentations.
The conference featured therapeutic workshops highlighting the latest developments in treatments for diseases such as the Hepatitis C virus, obesity, cancer and Alzheimer’s disease.
The opening plenary session highlighted the array of financing options and implications of pursuing those options when running a business and managing shareholder value and dilution. The meeting closed with attendees filling the room to hear from leading public and private investors in a plenary session entitled The Last Word on the Biotech Watch List for 2008 in which panelists highlighted the biggest trends that will impact the industry in the near future.
“Investment in biotech funding overall is growing to new heights and we’re in a pretty good place right now from a market standpoint,” said Eisenberg. “The BIO Investor Forum offered attendees the chance to learn what’s in store,” said Eisenberg.
The BIO Investor Forum hosts public and private equity investors, research analysts, investment bankers and senior-level industry executives focused on investment trends and business development opportunities in the life sciences. The conference included public and venture-stage company presentations, one-on-one investor meetings and numerous networking opportunities.
Upcoming BIO Events
BIO-Europe 2007 International Partnering Conference
November 12-14, 2007
Pacific Rim Summit on Industrial Biotechnology and Bioenergy
November 14-16, 2007
World Congress on Industrial Biotechnology & BioProcessing
April 27-30, 2008
2008 BIO International Convention
June 17-20, 2008
San Diego, Calif.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world’s largest gathering of the biotechnology industry.
Visit www.bio.org for more information on BIO and all upcoming events.